On April 27, 2026, Mirum Pharmaceuticals announced that its Phase 2b AZURE-1 study of brelovitug for treating chronic hepatitis delta virus met its primary endpoint, with 100% of patients in the 300 mg weekly group showing virologic response. The results also indicated a 45% composite endpoint achievement in the same group, compared to 0% in the delayed treatment arm, suggesting strong efficacy and a positive outlook for future studies.